Bioverativ Inc (BIVV) Receives $61.88 Consensus Target Price from Analysts
Bioverativ Inc (NASDAQ:BIVV) has earned an average recommendation of “Hold” from the seventeen brokerages that are currently covering the company, MarketBeat Ratings reports. Thirteen analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $61.88.
Several equities research analysts recently issued reports on BIVV shares. Jefferies Group lifted their price target on shares of Bioverativ to $79.00 and gave the company a “buy” rating in a report on Thursday, January 18th. Zacks Investment Research raised shares of Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 price target on the stock in a report on Monday, January 8th. Morgan Stanley raised shares of Bioverativ from an “underweight” rating to an “equal weight” rating in a report on Tuesday, January 23rd. Deutsche Bank set a $53.00 price target on shares of Bioverativ and gave the company a “hold” rating in a report on Monday, November 20th. Finally, Raymond James Financial lowered shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 23rd.
Institutional investors and hedge funds have recently bought and sold shares of the business. Robeco Institutional Asset Management B.V. bought a new stake in Bioverativ during the 4th quarter worth approximately $105,000. American Assets Investment Management LLC bought a new stake in shares of Bioverativ in the 4th quarter valued at $108,000. Advisors Asset Management Inc. bought a new stake in shares of Bioverativ in the 3rd quarter valued at $137,000. TCI Wealth Advisors Inc. bought a new stake in shares of Bioverativ in the 3rd quarter valued at $186,000. Finally, Ladenburg Thalmann Financial Services Inc. bought a new stake in shares of Bioverativ in the 3rd quarter valued at $190,000. 94.10% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.watchlistnews.com/bioverativ-inc-bivv-receives-61-88-consensus-target-price-from-analysts/1863858.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.